This trial has completed recruitment on this platform, and is no longer accepting new referrals.
A research study conducted by Moderna is testing an investigational vaccine that may protect people from RSV. RSV is a common cause of respiratory tract infection and may cause severe disease, especially in younger children and older adults.
Trial ID: NCT04528719-
The mRNA-1345-P101 study is evaluating the safety and immune response of an investigational vaccine, called mRNA-1345, to protect against RSV.
RSV can cause infections of the lungs and respiratory tract. Symptoms can be similar to a cold, and may include runny nose, sore throat, cough, and headache. However, RSV can lead to serious conditions like pneumonia especially for younger children and older adults. Currently there is not an approved vaccine for RSV.
Participation in the mRNA-1345-P101 Study lasts approximately 16 months (or through the RSV season after the last vaccination) and includes phone calls and up to eleven visits to the study site.
Insurance is not needed to join this clinical trial, and compensation for your time will be available.
You will need to bring your child to one of the study clinics taking part in this clinical trial.